PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA

PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA

Bibliographic Details
Main Authors:	E. Zerkalenkova, S. Lebedeva, A. Borkovskaia, Y. Menchits, M. Gaskova, A. Itov, E. Matveev, M. Kazanov, Y. Olshanskaya
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000850048.50885.7c

Similar Items

Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia
by: Lina Marie Hoffmeister, et al.
Published: (2021-09-01)

P435: NOVEL COMPOUNDS TO TARGET KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
by: Claudia Tregnago, et al.
Published: (2023-08-01)

Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia
by: Claudia Tregnago, et al.
Published: (2022-01-01)

<i>BTK</i>, <i>NUTM2A,</i> and <i>PRPF19</i> Are Novel <i>KMT2A</i> Partner Genes in Childhood Acute Leukemia
by: Elena Zerkalenkova, et al.
Published: (2021-07-01)

Integration of Transcriptomic Features to Improve Prognosis Prediction of Pediatric Acute Myeloid Leukemia With KMT2A Rearrangement
by: Jun Li, et al.
Published: (2023-12-01)

Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements
by: Ka‐Yuk Yuen, et al.
Published: (2023-01-01)

Lineage switch in relapse of acute leukemia with rearrangement of MLL gene (KMT2A). literature review and case reports
by: E. A. Zerkalenkova, et al.
Published: (2016-08-01)

P511: INTEGRATION OF TRANSCRIPTOMIC FEATURES IMPROVES PROGNOSIS PREDICTION OF PEDIATRIC ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENTS
by: Jun LI, et al.
Published: (2023-08-01)

INFANT EXTRAMEDULLARY KMT2A REARRANGED T/MYELOID ACUTE LEUKEMIA MIMICKING LANGERHANS CELL HISTIOCYTOSIS
by: Barbora Vakrmanova, et al.
Published: (2023-12-01)

Updates in <i>KMT2A</i> Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia
by: Mateusz Górecki, et al.
Published: (2023-03-01)

Acute Lymphoblastic Leukemia at Birth with KMT2A Gene Rearrangement
by: Sanjeev Kumar Jha, et al.

Molecular Heterogeneity of Pediatric AML with Atypical Promyelocytes Accumulation in Children—A Single Center Experience
by: Aleksandra Borkovskaia, et al.
Published: (2023-03-01)

Monocytic and blastic plasmacytoid dendritic cell differentiation in acute leukemia with KMT2A rearrangement
by: Owen Xue, et al.
Published: (2023-08-01)

Unusual Presentation of <i>SET::NUP214</i>-Associated Concomitant Hematological Neoplasm in a Child—Diagnostic and Treatment Struggle
by: Yaroslav Menchits, et al.
Published: (2023-09-01)

P527: DISTINCTIVE CLONAL EVOLUTION PATTERN AND PROGNOSTIC SIGNIFICANCE OF THE CLONALITY OF KRAS MUTATIONS IN KMT2A-REARRANGED ACUTE MYELOID LEUKEMIA
by: Hidemasa Matsuo, et al.
Published: (2023-08-01)

Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation
by: Xavier Thomas
Published: (2024-02-01)

Case report: Genomic analysis of a therapy-related chronic myelomonocytic leukemia with KMT2A rearrangement that progressed to acute myeloid leukemia with acute promyelocytic leukemia-like features
by: Tomotaka Suzuki, et al.
Published: (2023-02-01)

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
by: Verena I. Gaidzik, et al.
Published: (2023-05-01)

Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements
by: Jinquan Wen, et al.
Published: (2022-08-01)

Acute myeloid leukemia cutis with KMT2A::MLLT3 fusion presenting with leonine facies
by: Bret Wankel, et al.
Published: (2024-01-01)

PB1803: SMAD1 IS A TUMOR SUPPRESSOR IN ACUTE MYELOID LEUKEMIA WITH MLL REARRANGEMENT
by: Lisa Dietsche, et al.
Published: (2023-08-01)

The Impact of PI3-kinase/RAS Pathway Cooperating Mutations in the Evolution of KMT2A-rearranged Leukemia
by: Maria Teresa Esposito
Published: (2019-06-01)

FISH improves risk stratification in acute leukemia by identifying KMT2A abnormal copy number and rearrangements
by: Qinlu Li, et al.
Published: (2022-06-01)

KMT2D Deficiency Promotes Myeloid Leukemias which Is Vulnerable to Ribosome Biogenesis Inhibition
by: Jing Xu, et al.
Published: (2023-07-01)

Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy
by: Alexandra Semchenkova, et al.
Published: (2022-04-01)

Synergistic Effects of the RAR<i>alpha</i> Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation
by: Maximilian Fleischmann, et al.
Published: (2024-03-01)

PB1819: KMT2A::ARHGEF12 RARE FUSION ASSOCIATED WITH A NOVEL GERMLINE DDX41 VARIANT IN ACUTE MYELOID LEUKEMIA
by: Maxime Roubinet, et al.
Published: (2023-08-01)

Single-cell diploid Hi-C reveals the role of spatial aggregations in complex rearrangements and KMT2A fusions in leukemia
by: Zhihao Xing, et al.
Published: (2022-08-01)

NUP-98 Rearrangements Led to the Identification of Candidate Biomarkers for Primary Induction Failure in Pediatric Acute Myeloid Leukemia
by: Vincenza Barresi, et al.
Published: (2021-04-01)

P385: DETECTION OF KMT2A PARTIAL TANDEM DUPLICATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS BY NGS
by: A. Artigas-Baleri, et al.
Published: (2022-06-01)

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes
by: Pedro Casado, et al.
Published: (2023-02-01)

Widespread myeloid sarcoma with KMT2A rearrangement involving the testis, oral cavity, heart, kidney and gallbladder without bone marrow involvement
by: Rohan Kapur, et al.
Published: (2022-01-01)

Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia
by: Schneider, P, et al.
Published: (2023)

Duplex Sequencing Uncovers Recurrent Low-frequency Cancer-associated Mutations in Infant and Childhood KMT2A-rearranged Acute Leukemia
by: Mattias Pilheden, et al.
Published: (2022-10-01)

Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia
by: Pauline Schneider, et al.
Published: (2023-09-01)

XRCC4 rs28360071 intronic variant is associated with increased risk for infant acute lymphoblastic leukemia with KMT2A rearrangements
by: Orlando Louzada-Neto, et al.
Published: (2020-12-01)

PB1760: AZACITIDINE AS TREATMENT OF KMT2A INFANT ACUTE LYMPHOBLASTIC LEUKEMIA: SINGLE CENTER EXPERIENCE
by: G. Giagnuolo, et al.
Published: (2022-06-01)

Bone Marrow Microenvironment-Induced Chemoprotection in <i>KMT2A</i> Rearranged Pediatric AML Is Overcome by Azacitidine–Panobinostat Combination
by: Kara M. Lehner, et al.
Published: (2023-06-01)

CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in <i>KMT2A</i>-Rearranged Acute Lymphoblastic Leukemia
by: Pauline Schneider, et al.
Published: (2023-08-01)

Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia
by: Mawar Karsa, et al.
Published: (2022-01-01)